Qiagen N.V. (NASDAQ:QGEN) Analyst Rating Consensus

Qiagen N.V. (NASDAQ:QGEN) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 2.75 by 12 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 9 Brokerage Firms have advised hold. A sell rating was given by 1 analyst.

Other Equity analysts have also commented on the company shares. Citigroup maintains its view on Qiagen N.V. (NASDAQ:QGEN) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Citigroup lowers the price target from $28 per share to $25 per share on Qiagen N.V.. The rating by the firm was issued on March 15, 2016.

Qiagen N.V. (NASDAQ:QGEN): 8 Analyst have given the stock of Qiagen N.V. (NASDAQ:QGEN) a near short term price target of $24.25. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $1.83. The higher price target estimate is at $27 while the lower price estimates are fixed at $22.

Qiagen N.V. (NASDAQ:QGEN) rose 1.62% or 0.34 points on Tuesday and made its way into the gainers of the day. After trading began at $21.09 the stock was seen hitting $21.465 as a peak level and $20.93 as the lowest level. The stock ended up at $21.39. The daily volume was measured at 1,721,174 shares. The 52-week high of the share price is $28.53 and the 52-week low is $20.1. The company has a market cap of $4,992 million.

Shares of Qiagen NV appreciated by 3.08% during the last five trading days but lost 0.14% on a 4-week basis. Qiagen NV has dropped 2.51% during the last 3-month period . Year-to-Date the stock performance stands at -22.64%.

QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.